

[Fig.1]




[Fig.2]




[Fig.3]




[Fig. 4A]


(a)
U-87 MG
(b)
T-47D
Cell Viability (%)
120.0
100.0
80.0
60.0
40.0
20.0
0.0
No virus
IHD-W VTK
Lister VTK
WR ViTiKi
Brain cancer
Breast cancer
(c)
A2780
(d)
MIA PaCa-2
Ovarian cancer
Pancreatic cancer
(e)
A549
(f)
SW620
Lung cancer
Colorectal cancer


[Fig. 4B]


(a)
Hep3B
Cell Viability (%)
120.0
100.0
80.0
60.0
40.0
20.0
0.0
No virus
IHD-W VTK
Lister VTK
WR ViTiKi
Liver cancer
(b)
DU145
Prostate cancer
(c)
FaDu
Head and neck cancer
(d)
HT-1080
Fibrosarcoma


[Fig. 5]




[Fig. 6]


(a)
1.2
0.9
0.6
0.3
0
Fold difference of Normalized Potency
K
VT
VTK
IHD-W
(b)
1.2
0.9
0.6
0.3
0
Fold difference of Normalized Potency
ViTi
ViTiKi
WR


[Fig. 7]


(a)
2500
2000
1500
1000
500
0
Tumor volume (mm³)
PBS
IHD-W_VT
IHD-W_VTK
0d
2d
5d
8d
12d
15d
19d
21d
(days)
Virus injection
(b)
2500
2000
1500
1000
500
0
Tumor volume (mm³)
PBS
WR_ViTiKi
WR_ViTi
0d
3d
7d
10d
14d
17d
21d
24d
28d
31d
36d
40d
44d
(days)
Virus injection

[Fig. 8]



(a)
Net Body weight (%)
25
15
5
-5
-15
-25
0d
2d
5d
8d
12d
15d
19d
21d
49d
IHD-W_VTK
IHD-W_VT
Virus injection
(b)
Net Body weight (%)
25
15
5
-5
-15
-25
0d
3d
7d
10d
14d
17d
21d
24d
28d
31d
36d
40d
44d
WR_ViTiKi
WR_ViTi
Virus injection

[Fig. 9]


(a)
100
80
60
40
20
0
Death rate (%)
34%
0%
IHD-W/VT
IHD-W/VTK
(b)
100
80
60
40
20
0
Death rate (%)
34%
0%
WR_ViTi
WR_ViTiKi

[Fig. 10]

(a)



(b)

